Sanofi-Aventis is not being bashful about its designs on Genzyme any longer. The French pharma giant has offered $69 (£45) per share in an all-cash bid that values the US biotech at $18.5 billion. But so far Genzyme is having none of it: ’the Genzyme board is not prepared to ...